Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

Rhea-AI Summary

Science 37 has appointed Tyler Van Horn as its new CEO, effective January 14, 2025. Van Horn, previously the Chief Commercial Officer, has played a key role in driving operational excellence and shaping strategic initiatives that prioritize client success, contributing significantly to the company's growth since he joined in 2021.

His tenure has seen the assembly of a team capable of matching or surpassing traditional clinical trial standards, with a focus on patient well-being and safety through at-home services. Van Horn emphasizes the importance of enabling therapies to reach their endpoints faster, gaining approval, and ensuring equitable health outcomes. He aims to support sponsors with world-class research teams and innovative solutions, particularly targeting underserved populations.

Van Horn's elevation to CEO is set to build on past successes while reinforcing the company's commitment to growth, innovation, and enhanced solution delivery. Science 37 continues to lead in patient access, diversity, and safety in clinical research.

Positive

• Appointment of Tyler Van Horn as CEO, bringing continuity and proven leadership.
• Van Horn's focus on operational excellence and strategic initiatives that have driven company growth.
• Commitment to patient well-being, safety, and at-home services.
• Emphasis on accelerating therapy endpoints, gaining approvals, and ensuring equitable health outcomes.
• Targeting underserved populations with innovative solutions.

Negative

• None.

Seasoned Strategist and Former Chief Commercial Officer Poised to Accelerate Access and Equity in Clinical Research

MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company’s Chief Commercial Officer, Van Horn’s appointment follows his pivotal role in driving operational excellence and shaping the company’s strategic direction to better prioritize client success – initiatives credited with driving growth for the company.

Since joining Science 37 in 2021, Van Horn has been a chief architect in assembling and empowering a team capable of matching or surpassing the testing standards and data quality of traditional clinical trial sites. By emphasizing the well-being and safety of patients through the delivery of convenient, at-home services, Van Horn sees Science 37 solving the most acute patient enrollment and study conduct pain points facing its clinical research clients.

“The future of clinical research lies in enabling therapies to reach their endpoints faster, gaining approval, and ensuring equitable, improved health outcomes for all,” said Van Horn. “As CEO, I am dedicated to supporting sponsors with our world-class research teams and innovative solutions. Our commitment to expanding patient access remains at the heart of everything we do, especially as we strive to reach underserved populations and drive meaningful change in healthcare.”

Van Horn’s elevation to CEO positions Science 37 to seamlessly build upon the learning of past successes. It also redoubles the company’s commitment to growth through purposeful innovation and enhanced solution delivery. By prioritizing the patient and study sponsors, Science 37 is leading the way, ushering in a new era of accessibility, diversity, and patient safety in clinical research.

For more information about Science 37 and its unique approach to clinical research, visit www.science37.com.

About Science 37

Science 37 accelerates clinical research by expanding patient access to trials, leading to faster approvals and better health outcomes. Our Metasite™ and Patient Recruitment solutions enable life sciences companies to reach beyond traditional means of conducting clinical research. To learn more, visit www.science37.com, or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.

Media Inquiries

Science 37
pr@science37.com

FAQ

Who is the new CEO of Science 37?

Tyler Van Horn has been appointed as the new CEO of Science 37.

When did Tyler Van Horn become CEO of Science 37?

Tyler Van Horn became CEO of Science 37 on January 14, 2025.

What was Tyler Van Horn's role before becoming CEO of Science 37?

Before becoming CEO, Tyler Van Horn was the Chief Commercial Officer of Science 37.

How has Tyler Van Horn contributed to Science 37's growth?

Tyler Van Horn drove operational excellence and strategic initiatives that prioritized client success, contributing significantly to Science 37's growth.

What are Tyler Van Horn's priorities as CEO of Science 37?

As CEO, Tyler Van Horn prioritizes patient well-being, safety, at-home services, and reaching therapy endpoints faster, with a focus on equitable health outcomes.

How does Science 37 plan to expand patient access under the new CEO?

Under Tyler Van Horn, Science 37 plans to expand patient access by targeting underserved populations with innovative solutions and world-class research teams.

What impact will Tyler Van Horn's appointment have on Science 37's clinical research?

Tyler Van Horn's appointment as CEO is expected to reinforce Science 37's commitment to growth, innovation, and enhanced solution delivery in clinical research.